Zhang Xin-Xin, Gan Yong, Yang Xing-Gang, Zhu Chun-Liu, Gan Li, Nie Shu-Fang, Pan Wei-San
School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
Yao Xue Xue Bao. 2008 Jan;43(1):91-6.
Hydroxycamptothecin (HCPT) loaded PEG modified nanostructured lipid carriers (HCPT-PEG-NLC) and nanostructured lipid carriers (HCPT-NLC) were prepared by melt emulsification and homogenization method. The morphology, particle size and encapsulation efficiency of them were investigated. HCPT concentrations in plasma, heart, liver, spleen, lung, kidney and ovary were determined after iv of HCPT injection, HCPT-PEG-NLC and HCPT-NLC in mice. The targeting indexes of HCPT-PEG-NLC and HCPT-NLC were calculated. The transmission electron microscope imaging showed that HCPT-PEG-NLC and HCPT-NLC exhibited a spherical shape. The particle sizes of them were (88.6 +/- 22.5) and (127.2 +/- 43.4) nm. The encapsulation efficiency were (90.51 +/- 3.29)% and (84.37 +/- 2.81)%, respectively. After iv injection into the tail vein of mice, HCPT plasma concentrations of HCPT-PEG-NLC and HCPT-NLC were higher than that of HCPT injection at each sampling time. They also showed longer elimination time in every tissue. HCPT-NLC accumulated in endothelial system (RES), Re and Ce of it in liver and spleen were significantly higher than HCPT-PEG-NLC. HPCT-PEG-NLC prolonged circulation time and increased bioavailability of HCPT. MRT and AUC0-24 h of it were 19.80 and 17.02 times higher than those of HCPT injection. It also significantly reduced phagocytosis of RES, and showed lung targeting effect (Re and Ce were 14.51 and 41.35). To summarize, HCPT-PEG-NLC could prolong the circulation time of HCPT in vivo, and had the lung targeting effect. It was a promising carrier to increase therapeutic effect of HCPT in treating lung cancer.
采用熔融乳化-匀质法制备了载羟基喜树碱(HCPT)的聚乙二醇修饰的纳米结构脂质载体(HCPT-PEG-NLC)和纳米结构脂质载体(HCPT-NLC)。考察了它们的形态、粒径及包封率。给小鼠静脉注射HCPT注射液、HCPT-PEG-NLC和HCPT-NLC后,测定血浆、心脏、肝脏、脾脏、肺、肾脏和卵巢中HCPT的浓度。计算HCPT-PEG-NLC和HCPT-NLC的靶向指数。透射电子显微镜成像显示,HCPT-PEG-NLC和HCPT-NLC呈球形。它们的粒径分别为(88.6±22.5)和(127.2±43.4)nm。包封率分别为(90.51±3.29)%和(84.37±2.81)%。小鼠尾静脉注射后,在各取样时间点,HCPT-PEG-NLC和HCPT-NLC的HCPT血浆浓度均高于HCPT注射液。它们在各组织中的消除时间也更长。HCPT-NLC在内皮系统(RES)中蓄积,其在肝脏和脾脏中的相对摄取率(Re)和靶向效率(Ce)显著高于HCPT-PEG-NLC。HPCT-PEG-NLC延长了HCPT的循环时间并提高了其生物利用度。其平均滞留时间(MRT)和0~24小时血药浓度-时间曲线下面积(AUC0-24 h)分别是HCPT注射液的19.80倍和17.02倍。它还显著降低了RES的吞噬作用,并显示出肺靶向作用(Re和Ce分别为14.51和41.35)。综上所述,HCPT-PEG-NLC可延长HCPT在体内的循环时间,并具有肺靶向作用。它是一种有望提高HCPT治疗肺癌疗效的载体。